Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Article Details
- CitationCopy to clipboard
Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T
Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Drug Metab Dispos. 1999 Dec;27(12):1381-91.
- PubMed ID
- 10570018 [ View in PubMed]
- Abstract
Azelastine, an antiallergy and antiasthmatic drug, has been reported to be mainly N-demethylated to desmethylazelastine in humans. In the present study, Eadie-Hofstee plots of azelastine N-demethylation in human liver microsomes were biphasic. In microsomes from human B-lymphoblast cells, recombinant cytochrome P-450 (CYP)2D6 and CYP1A1 exhibited higher azelastine N-demethylase activity than did other CYP enzymes. On the other hand, recombinant CYP3A4 and CYP1A2 as well as CYP1A1 and CYP2D6 in microsomes from baculovirus-infected insect cells were active in azelastine N-demethylation. The K(M) value of the recombinant CYP2D6 (2.1 microM) from baculovirus-infected insect cells was similar to the K(M) value of the high-affinity (2.4+/-1.3 microM) component in human liver microsomes. On the other hand, the K(M) values of the recombinant CYP3A4 (51.1 microM) and CYP1A2 (125.4 microM) from baculovirus-infected insect cells were similar to the K(M) value of the low-affinity (79.7+/-12.8 microM) component in human liver microsomes. Bufuralol inhibited the high-affinity component, making the Eadie-Hofstee plot in human liver microsomes monophasic. Azelastine N-demethylase activity in human liver microsomes (5 microM azelastine) was inhibited by ketoconazole, erythromycin, and fluvoxamine (IC(50) = 0.08, 18.2, and 17.2 microM, respectively). Azelastine N-demethylase activity in microsomes from twelve human livers was significantly correlated with testosterone 6beta-hydroxylase activity (r = 0.849, p<.0005). The percent contributions of CYP1A2, CYP2D6, and CYP3A4 in human livers were predicted using several approaches based on the concept of correction with CYP contents or relative activity factors (RAFs). Our data suggested that the approach using RAF(CL) (RAF as the ratio of clearance) is most predictive of the N-demethylation clearance of azelastine because it best reflects the observed N-demethylation clearance in human liver microsomes. Summarizing the results, azelastine N-demethylation in humans liver microsomes is catalyzed mainly by CYP3A4 and CYP2D6, and CYP1A2 to a small extent (in average, 76.6, 21.8, and 3.9%, respectively), although the percent contribution of each isoform varied among individuals.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Azelastine Cytochrome P450 1A1 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 1A2 Protein Humans UnknownSubstrateDetails Azelastine Cytochrome P450 2A6 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 2C19 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 2C8 Protein Humans UnknownSubstrateDetails Azelastine Cytochrome P450 2C9 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 2D6 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorDetails Azelastine Cytochrome P450 3A5 Protein Humans UnknownSubstrateDetails - Drug Reactions
Reaction Details
